Phase I Trial of Fixed Dose Rate Infusion Gemcitabine with Gefitinib in Patients with Pancreatic Carcinoma

REFERENCES

• Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J. Clin. 2005; 55: 10–30
   PubMed Web of Science ®Google Scholar
• Burris H. A., III, Moore M. J., Andersen J., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997; 15: 2403–2413
   PubMed Web of Science ®Google Scholar
• Rocha Lima C. M., Green M. R., Rotche R., et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J. Clin. Oncol 2004; 22: 3776–3783
   PubMed Web of Science ®Google Scholar
• Berlin J. D., Catalano P., Thomas J. P., , Phase I II, et al. study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J. Clin. Oncol. 2002; 20: 3270–3275
   PubMed Web of Science ®Google Scholar
• Bramhall S. R., Schulz J., Nemunaitis J., et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br. J. Cancer 2002; 87: 161–167
   PubMed Web of Science ®Google Scholar
• Louvet C., Labianca R., Hammel P., et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J. Clin. Oncol. 2005; 23: 3509–3516
   PubMed Web of Science ®Google Scholar
• Van Cutsem E., van, d. V., Karasek P., et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J. Clin. Oncol. 2004; 22: 1430–1438
   PubMed Web of Science ®Google Scholar
• Oettle H., Richards D., Ramanathan R. K., et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann. Oncol. 2005; 16: 1639–1645
   PubMed Web of Science ®Google Scholar
• Lemoine N. R., Hughes C. M., Barton C. M., et al. The epidermal growth factor receptor in human pancreatic cancer. J. Pathol. 1992; 166: 7–12
   PubMed Web of Science ®Google Scholar
• Xiong H. Q., Abbruzzese J. L. Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Semin. Oncol. 2002; 29: 31–37
   PubMed Web of Science ®Google Scholar
• Bruns C. J., Harbison M. T., Davis D. W., et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin. Cancer Res. 2000; 6: 1936–1948
   PubMed Web of Science ®Google Scholar
• Xiong H. Q., Rosenberg A., LoBuglio A., et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J. Clin. Oncol. 2004; 22: 2610–2616
   PubMed Web of Science ®Google Scholar
• Moore M., Goldstein D., Hamm J., et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. Proc. Am. Soc. Clin. Oncol. 2005; 23: 1
   PubMed Web of Science ®Google Scholar
• Grunewald R., Abbruzzese J. L., Tarassoff P., Plunkett W. Saturation of 2′,2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother. Pharmacol. 1991; 27: 258–262
   PubMed Web of Science ®Google Scholar
• Brand R., Capadano M., Tempero M. A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors. Invest. New Drugs 1997; 15: 331–341
   PubMed Web of Science ®Google Scholar
• Tempero M., Plunkett W., Ruiz V. H. V., et al. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J. Clin. Oncol. 2003; 21: 3402–3408
   PubMed Web of Science ®Google Scholar
• Poplin E., Levy D., Berlin J., et al. Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR]) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201). Proc. Am. Soc. Clin. Oncol. 2006; 24: LBA4004
   Google Scholar
• Giaccone G., Gonzalez-Larriba J. L., van Oosterom A. T., et al. Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors. Ann. Oncol. 2004; 15: 831–838
   PubMed Web of Science ®Google Scholar
• Giaccone G., Herbst R. S., Manegold C., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial–INTACT 1. J. Clin. Oncol. 2004; 22: 777–784
   PubMed Web of Science ®Google Scholar
• Kris M. G., Natale R. B., Herbst R. S., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290: 2149–2158
   PubMed Web of Science ®Google Scholar
• Cancer therapy evaluation program. Common toxicity criteria, version 2.0. Division of Cancer Treatment & Diagnosis, National Institutes of Health, Bethesda, MD March, 1998
   Google Scholar
• Therasse P., Arbuck S. G., Eisenhauer E. A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 2000; 92: 205–216
   PubMed Web of Science ®Google Scholar
• Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J. Clin. Oncol. 2003; 21: 2237–2246
   PubMed Web of Science ®Google Scholar